198 related articles for article (PubMed ID: 27073652)
1. A prospective feasibility study to evaluate neoadjuvant-synchronous S-1 with radiotherapy for locally advanced rectal cancer: A multicentre phase II trial.
Inomata M; Akagi T; Nakajima K; Etoh T; Tahara K; Matsumoto T; Ogawa T; Fujii K; Shiromizu A; Kitano S
Mol Clin Oncol; 2016 Apr; 4(4):510-514. PubMed ID: 27073652
[TBL] [Abstract][Full Text] [Related]
2. Long-term outcomes of neoadjuvant-synchronous S-1 plus radiotherapy for locally advanced rectal cancer: a multi-institutional prospective phase II study.
Hiratsuka T; Etoh T; Hara T; Akagi T; Tahara K; Matsumoto T; Ogawa T; Fujii K; Shiromizu A; Shiroshita H; Inomata M
J Anus Rectum Colon; 2018; 2(4):168-175. PubMed ID: 31559360
[TBL] [Abstract][Full Text] [Related]
3. Prospective feasibility study to evaluate neoadjuvant-synchronous S-1 + RT for locally advanced rectal cancer: a multicenter phase II trial (UMIN ID: 03396).
Inomata M; Akagi T; Nakajima K; Etoh T; Shiraishi N; Tahara K; Matsumoto T; Kinoshita T; Fujii K; Shiromizu A; Kubo N; Kitano S
Jpn J Clin Oncol; 2013 Mar; 43(3):321-3. PubMed ID: 23275647
[TBL] [Abstract][Full Text] [Related]
4. Korean Society of Coloproctology (KSCP) trial of cONsolidation Chemotherapy for Locally advanced mid or low rectal cancer after neoadjUvant concurrent chemoraDiothErapy: a multicenter, randomized controlled trial (KONCLUDE).
Kim CW; Kang BM; Kim IY; Kim JY; Park SJ; Park WC; Bae KB; Bae BN; Baek SK; Baik SH; Son GM; Lee YS; Lee SH
BMC Cancer; 2018 May; 18(1):538. PubMed ID: 29739356
[TBL] [Abstract][Full Text] [Related]
5. Outcomes of neoadjuvant chemoradiotherapy followed by total mesorectal excision surgery for locally advanced rectal cancer: a single-institution experience.
Tseng MSF; Zheng H; Ng IWS; Leong YH; Leong CN; Yong WP; Cheong WK; Tey JCS
Singapore Med J; 2018 Jun; 59(6):305-310. PubMed ID: 29167909
[TBL] [Abstract][Full Text] [Related]
6. Pre-operative chemoradiation for non-metastatic locally advanced rectal cancer.
McCarthy K; Pearson K; Fulton R; Hewitt J
Cochrane Database Syst Rev; 2012 Dec; 12():CD008368. PubMed ID: 23235660
[TBL] [Abstract][Full Text] [Related]
7. Total neoadjuvant approach with FOLFOXIRI plus bevacizumab followed by chemoradiotherapy plus bevacizumab in locally advanced rectal cancer: the TRUST trial.
Masi G; Vivaldi C; Fornaro L; Lonardi S; Buccianti P; Sainato A; Marcucci L; Martignetti A; Luca Urso ED; Castagna M; Fontanini G; Bergamo F; Musettini G; Urbani L; Sensi E; Balestri R; Montrone S; Pasqualetti F; Cremolini C; Di Paolo A; Zagonel V; Falcone A
Eur J Cancer; 2019 Mar; 110():32-41. PubMed ID: 30739838
[TBL] [Abstract][Full Text] [Related]
8. [Preoperative chemoradiotherapy with S-1 for advanced low rectal cancer].
Kitani K; Okajima K; Sato K; Isono S; Kimura H; Ikeda M; Inoue K; Iwama M; Tsujie M; Nakayama T; Fujiwara Y; Murata M; Yukawa M; Ota Y; Inoue M
Gan To Kagaku Ryoho; 2011 Nov; 38(12):2122-4. PubMed ID: 22202303
[TBL] [Abstract][Full Text] [Related]
9. Long-term results of a multicenter phase II study of preoperative chemoradiotherapy with S-1 plus oxaliplatin for locally advanced rectal cancer (JACCRO CC-04: SHOGUN Trial).
Kondo K; Matsusaka S; Ishihara S; Horie H; Uehara K; Oguchi M; Murafushi K; Ueno M; Mizunuma N; Shimbo T; Kato D; Okuda J; Hashiguchi Y; Nakazawa M; Sunami E; Kawai K; Yamashita H; Okada T; Ishikawa Y; Fujii M; Nakajima T
Radiother Oncol; 2019 May; 134():199-203. PubMed ID: 31005216
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and Feasibility of Adding Induction Chemotherapy to Neoadjuvant Chemoradiation in Locally Advanced Rectal Cancer: A Phase II Clinical Trial.
Nasrolahi H; Mirzaei S; Mohammadianpanah M; Bananzadeh AM; Mokhtari M; Sasani MR; Mosalaei A; Omidvari S; Ansari M; Ahmadloo N; Hamedi SH; Khanjani N
Ann Coloproctol; 2019 Oct; 35(5):242-248. PubMed ID: 31725999
[TBL] [Abstract][Full Text] [Related]
11. A Phase II trial of neoadjuvant preoperative chemoradiotherapy with S-1 plus irinotecan and radiation in patients with locally advanced rectal cancer: clinical feasibility and response rate.
Sato T; Ozawa H; Hatate K; Onosato W; Naito M; Nakamura T; Ihara A; Koizumi W; Hayakawa K; Okayasu I; Yamashita K; Watanabe M
Int J Radiat Oncol Biol Phys; 2011 Mar; 79(3):677-83. PubMed ID: 21035953
[TBL] [Abstract][Full Text] [Related]
12. Neoadjuvant concurrent chemoradiotherapy followed by definitive high-dose radiotherapy or surgery for operable thoracic esophageal carcinoma.
Murakami M; Kuroda Y; Okamoto Y; Kono K; Yoden E; Kusumi F; Hajiro K; Matsusue S; Takeda H
Int J Radiat Oncol Biol Phys; 1998 Mar; 40(5):1049-59. PubMed ID: 9539559
[TBL] [Abstract][Full Text] [Related]
13. Preoperative chemoradiotherapy with oxaliplatin and tegafur-uracil in locally advanced rectal cancer: pathologic complete response rate and preliminary results of overall and disease-free survival in a single institute in Taiwan.
Chao JY; Wang HM; Chiang FF; Lin JC; Chang CF; Lin JF; Yeh HL
J Chin Med Assoc; 2014 Mar; 77(3):128-32. PubMed ID: 24398439
[TBL] [Abstract][Full Text] [Related]
14. Organ preservation for clinical T2N0 distal rectal cancer using neoadjuvant chemoradiotherapy and local excision (ACOSOG Z6041): results of an open-label, single-arm, multi-institutional, phase 2 trial.
Garcia-Aguilar J; Renfro LA; Chow OS; Shi Q; Carrero XW; Lynn PB; Thomas CR; Chan E; Cataldo PA; Marcet JE; Medich DS; Johnson CS; Oommen SC; Wolff BG; Pigazzi A; McNevin SM; Pons RK; Bleday R
Lancet Oncol; 2015 Nov; 16(15):1537-1546. PubMed ID: 26474521
[TBL] [Abstract][Full Text] [Related]
15. [Rectum-preserving surgery after consolidation neoadjuvant therapy or totally neoadjuvant therapy for low rectal cancer: a preliminary report].
Huang Y; Huang SH; Chi P; Wang XJ; Lin HM; Lu XR; Ye DX; Lin Y; Deng Y
Zhonghua Wei Chang Wai Ke Za Zhi; 2020 Mar; 23(3):281-288. PubMed ID: 32192308
[No Abstract] [Full Text] [Related]
16. Oxaliplatin added to fluorouracil-based preoperative chemoradiotherapy and postoperative chemotherapy of locally advanced rectal cancer (the German CAO/ARO/AIO-04 study): final results of the multicentre, open-label, randomised, phase 3 trial.
Rödel C; Graeven U; Fietkau R; Hohenberger W; Hothorn T; Arnold D; Hofheinz RD; Ghadimi M; Wolff HA; Lang-Welzenbach M; Raab HR; Wittekind C; Ströbel P; Staib L; Wilhelm M; Grabenbauer GG; Hoffmanns H; Lindemann F; Schlenska-Lange A; Folprecht G; Sauer R; Liersch T;
Lancet Oncol; 2015 Aug; 16(8):979-89. PubMed ID: 26189067
[TBL] [Abstract][Full Text] [Related]
17. Phase II trial of neoadjuvant chemotherapy with XELOX plus bevacizumab for locally advanced rectal cancer.
Uehara K; Ishiguro S; Sakamoto E; Maeda A; Inoue M; Tojima Y; Kobayashi S; Omiya N; Ishizuka N; Nakao A; Goto H; Nagino M
Jpn J Clin Oncol; 2011 Aug; 41(8):1041-4. PubMed ID: 21803876
[TBL] [Abstract][Full Text] [Related]
18. A multicenter phase II study of preoperative chemoradiotherapy with S-1 plus oxaliplatin for locally advanced rectal cancer (SHOGUN trial).
Matsusaka S; Ishihara S; Kondo K; Horie H; Uehara K; Oguchi M; Murofushi K; Ueno M; Mizunuma N; Shimbo T; Kato D; Okuda J; Hashiguchi Y; Nakazawa M; Sunami E; Kawai K; Yamashita H; Okada T; Ishikawa Y; Nakajima T; Watanabe T
Radiother Oncol; 2015 Aug; 116(2):209-13. PubMed ID: 26337743
[TBL] [Abstract][Full Text] [Related]
19. A phase II study of cetuximab, capecitabine and radiotherapy in neoadjuvant treatment of patients with locally advanced resectable rectal cancer.
Velenik V; Ocvirk J; Oblak I; Anderluh F
Eur J Surg Oncol; 2010 Mar; 36(3):244-50. PubMed ID: 20042310
[TBL] [Abstract][Full Text] [Related]
20. Pathologic response to neoadjuvant treatment in locally advanced rectal cancer and impact on outcome.
Jalilian M; Davis S; Mohebbi M; Sugamaran B; Porter IW; Bell S; Warrier SK; Wale R
J Gastrointest Oncol; 2016 Aug; 7(4):603-8. PubMed ID: 27563451
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
